Skip navigation
Corp_story_hero image

DNA is in our blood

Natera is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. Our mission is to change the management of disease worldwide by using information gained from a simple blood draw to proactively inform treatment.

Corporate Story Women's Health, Organ Health, Oncology

Next-generation cell-free DNA testing

Through our next-generation, cfDNA technology platform, we’ve pioneered noninvasive blood-based testing in the fields of women’s health, oncology, and organ health.

Focused on experience and support

At Natera, we’re building an entirely new way to manage genetic testing: in the cloud. We’ve made it possible to virtually order tests, schedule mobile blood draws, access test results, and consult with genetic counselors — all with the click of a button. Our global footprint spans 90 countries worldwide, putting cfDNA testing within reach.


Our mission is personal

Applying clinical expertise, leading-edge cell-free DNA technology, and operational excellence to change the management of disease worldwide

Corp_story_fact 1
Corp_story_fact 2
Corp_story_fact 3

Natera was born from a deeply personal desire to change the way disease was managed.

Matthew Rabinowitz

“In 2004, my sister gave birth to a son with Down Syndrome. He passed away six days after birth. It was a devastating experience for our entire family. I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.”

Since its founding, Natera has pushed the boundaries of testing management with a proven track record of scientific excellence and innovation.

2004Natera, Inc. is founded by Matthew Rabinowitz, Ph.D. and Jonathan Sheena, M. Eng
2009menu womens health iconSpectrum preimplantation genetic test introduced
2010menu womens health iconAnora miscarriage test (POC) introduced
2012menu womens health iconHorizon advanced carrier screening test introduced
2013menu womens health iconPanorama next-generation NIPT introduced
2015Natera, Inc. holds Initial Public Offering (IPO)
2016Natera and USCF collaborate on a study evaluating the use of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant patients
2017menu womens health iconVistara single-gene NIPT introduced
2017menu cancer iconSignatera molecular residual disease (MRD) test introduced (Research Use Only)
2017menu cancer iconStudy published in Nature shows early relapse detection in lung cancer using Natera’s circulating tumor DNA (ctDNA) technology
2018Natera and Fox Chase Cancer Center collaborate on kidney cancer study using the Signatera RUO test
2018menu cancer iconSignatera RUO Test shown to detect molecular residual disease up to 2 years prior to clinical relapse and to predict treatment response in breast cancer
2019Steve Chapman appointed CEO
2019menu cancer iconSignatera CLIA test introduced
2019FDA grants breakthrough device designation to Natera’s Signatera test
2019menu womens health iconPanorama NIPT achieves 2 million test milestone
2019menu renal health iconProspera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test introduced
2020menu womens health iconEmpower hereditary cancer test introduced
2020Natera expands lab footprint with a facility in Austin, Texas
2020menu renal health iconRenasight kidney gene panel introduced
2020menu cancer iconPublication in Nature Cancer shows Signatera’s ability to evaluate tumor response to immunotherapy